

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number  
WO 03/071283 A1

(51) International Patent Classification<sup>7</sup>: G01N 271/327,  
C12Q 1/00, 1/26, 1/32, H01M 6/00

(21) International Application Number: PCT/GB03/00751

(22) International Filing Date: 21 February 2003 (21.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0204232.3 22 February 2002 (22.02.2002) GB

(71) Applicant (for all designated States except US): **ISIS IN-  
NOVATION LIMITED** [GB/GB]; Ewert House, Ewert  
Place, Summertown, Oxford OX2 7SG (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WONG, Luet, Lok**  
[GB/GB]; University of Oxford, Inorganic Chemistry  
Laboratory, South Parks Road, Oxford OX1 3QR (GB).  
**BELL, Stephen** [GB/GB]; University Of Oxford, Inor-  
ganic Chemistry Laboratory, South Parks Road, Oxford  
OX1 3QR (GB).

(74) Agents: **ROQUES, Sarah, Elizabeth**, et al.; J.A. Kemp  
& Co., 14 South Square, Gray's Inn, London WC1R 5JJ  
(GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: ELECTROCHEMICAL DETECTION OF NADH OR NAPH

(57) Abstract: A method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample is provided, wherein the method comprises - contacting a reductase and a redox active agent to said sample; and - measuring the quantity of reduced redox active agent produced by the reductase, by electrochemical means. The method may be used to quantify the amount or activity of a redox enzyme or its substrate, wherein the redox enzyme uses NAD<sup>+</sup>, NADP<sup>+</sup>, NADPH or NADP as a cofactor.



WO 03/071283 A1

## ELECTROCHEMICAL DETECTION OF NADH OR NADPH

### Field of the Invention

This invention relates to assays for determining the amount of NADPH (nicotinamide adenine dinucleotide phosphate) or NADH (nicotinamide adenine  
5 dinucleotide) present in a sample. The assays may also be used to determine the activity or amount of a redox enzyme or its substrate.

### Background of the Invention

NADH and NADPH are physiological substances which occur in all living cells including human cells. Both are byproducts of a large number of redox enzymes and in  
10 particular dehydrogenases. Many dehydrogenases employ  $\text{NAD}^+$  or  $\text{NADP}^+$  as a cofactor. As the substrate of the dehydrogenase is oxidised,  $\text{NAD}^+$  or  $\text{NADP}^+$  is simultaneously reduced to NADH or NADPH. This reduction involves the transfer of two electrons plus a proton (or hydride transfer) to the  $\text{NAD}^+$  or  $\text{NADP}^+$  to generate the NADH or NADPH. In the case of some dehydrogenases, such as glutamate dehydrogenase, the reaction can be  
15 driven in the reverse direction.

A large range of dehydrogenases exist and carry out a number of biologically important functions. Substrates for the dehydrogenases include biological important compounds such as amino acids, lactate, cholesterol and glycerol. It is important to be able to monitor the amount of these compounds and assays exist which employ dehydrogenases  
20 to measure the amount of such metabolites in biological samples.

The assays typically measure the amount of NADH or NADPH produced as the dehydrogenase oxidises the substrate and hence allow the quantification of the substrate. These assays typically employ spectrophotometric methods to detect the amount of NADH or NADPH. However, such spectrophotometric assays are cumbersome and  
25 require skilled operators to carry them out. Additionally, problems or costs may be involved where the sample contains high amounts of a protein which absorbs at the wavelength being measured or structures such as blood cells which also interfere with the absorbance. This may mean extra processing steps have to be carried out.

Electrochemical methods have been attempted to try and measure the amount of  
30 NADH or NADPH. However, the only methods developed so far typically use organic

dyes such as Mendola blue and methyl-viologen or diaphorase as mediators and these are unstable and are frequently toxic. In addition, the electrochemical methods typically use electron acceptors that can only accept a single electron at a time from NADH or NADPH or which are too slow meaning that too small a current is produced or the current produced is not proportional to the amount of substrate present and hence quantitative results cannot be obtained.

#### Summary of the Invention

The present invention is based on the finding that a class of redox proteins known as reductases can simultaneously accept two electrons from NADH or NADPH and rapidly transfer them to a small, redox active molecule. The re-oxidation of the redox active molecule can then be detected, typically by using electrochemical methods. The fast rate of electron transfer reduction of the redox active small molecule complex by the reductase means that an effective, catalytic current can be generated which is limited by, and can be linear to, the substrate concentration. Thus results can be obtained which are truly quantitative. The method also allows measurement over time. Therefore NADH or NADPH can be effectively quantified electrochemically without the need for toxic, unstable organic dyes. The assay is also far simpler to carry out than those in the art, meaning less experience is required to carry it out and reducing its expense.

Accordingly, the present invention provides a method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample comprising;

- adding a reductase and a redox active agent to said sample; and
- measuring the quantity of reduced redox active agent produced by the reductase.

In particular, the invention provides a method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample comprising;

- contacting a reductase and a redox active agent with said sample; and
- measuring the quantity of reduced redox active agent produced by the reductase, by electrochemical means.

The invention further provides an electrochemical cell comprising:

- sample holding means;
- a source of reductase;

- a redox active agent; and
- means for detecting and/or quantifying any current generated.

The invention also provides a kit comprising:


- a reductase;
- 5 - a redox active agent; and
- a means for detecting the reduction of the redox active agent.

### Detailed description of the Invention

Throughout the present specification and the accompanying claims the words  
10 "comprise" and "include" and variations such as "comprises", "comprising", "includes" and  
"including" are to be interpreted inclusively. That is, these words are intended to convey  
the possible inclusion of other elements or integers not specifically recited, where the  
context allows.

#### *General scheme for Assay*

15 The general scheme for the assay system of the invention is as follows:



Although most commonly the assay scheme is as indicated above, the system can  
effectively be run in reverse, with electrons and a proton being transferred from the  
reductase to  $\text{NAD}^+$  or  $\text{NADP}^+$  to generate  $\text{NADH}$  or  $\text{NADPH}$  respectively. In this  
20 embodiment, the quantity of oxidised redox agent is monitored, for example by electron  
transfer to the electrode.

The assay can be used to detect and/or quantify the amount of the:

- redox enzyme;
- substrate; or

– NADH, NADPH, NAD<sup>+</sup>, or NADP<sup>+</sup> or an analog of any of these present in the biological sample. In particular, a direct measure of the amount of NADH or NADPH present or generated in the sample, can be correlated to the amount of substrate present in a sample, or amount of redox enzyme. In this embodiment, it is particularly  
5 useful to plot the generation of NADH/NADPH through the electrode via reductase and redox active agent, over time to elucidate the activity and thus presence and amount of the redox enzyme present.

The assay system can also involve additional steps. For example, additional stages may be involved after the reductase or before the redox enzyme indicated above. Such  
10 additional steps may also involve the transfer of electrons and will typically be enzyme catalysed. Where there are additional steps before the redox enzyme which converts NAD<sup>+</sup> or NADP<sup>+</sup> to NADH or NADPH or *vice versa* the purpose of the assay may be to measure the amount of an enzyme or compound upstream of the redox enzyme.

In one embodiment, the upstream events involve the release of a bound substance  
15 which can then be detected. Typically, the bound substance is released enzymatically. For example the bound substance may be cholesterol and the enzyme catalysing its release may be a lipase. Other substances or cofactors, such as a detergent, may also be present. Once released the substance, such as cholesterol, is then a substrate for the redox enzyme. Such assays are used to detect the presence or absence of, or to quantify the amount of, either the  
20 bound substance such as cholesterol or the enzyme catalysing its release such as lipase. Preferably the assay is used to detect and/or quantify the bound substance.

#### *Analyte or enzyme to be measured*

The redox enzyme responsible for the initial step in the assay can be any of a number of possible enzymes and the assay may be used to measure the amount of that  
25 enzyme or its substrate. The enzyme is matched with the substrate so that appropriate pairings are chosen such that the enzyme can oxidise or reduce the substrate using the nicotinamide adenine dinucleotide as a cofactor. Typically the enzyme oxidises the substrate and reduces NAD<sup>+</sup>, or NADP<sup>+</sup>. The enzyme may be a recombinant enzyme or one from a natural source.

30 Examples of possible enzymes which can be used or quantified include glycerol dehydrogenase, glucose dehydrogenase, glutamate dehydrogenase, cholesterol

dehydrogenase, ethylene glycol dehydrogenase, lactate dehydrogenase, alcohol dehydrogenase,  $\alpha$ -hydroxybutyrate dehydrogenase, isocitric dehydrogenase, sorbitol dehydrogenase, aspartate aminotransferase, and alanine amino-transferase. In a preferred embodiment of the invention the redox enzyme is a dehydrogenase and more preferably is  
5 glycerol dehydrogenase, glucose dehydrogenase glutamate dehydrogenase, ethylene glycol dehydrogenase, cholesterol dehydrogenase, lactate dehydrogenase, or alcohol dehydrogenase.

Any of a large number of compounds can be used as the substrate. The substrate may be a biologically important molecule such as urea, uric acid, ammonia, lactic acid,  
10 triglyceride, LDL, salicylate, glucose, pyruvic acid, carbon dioxide, adenosine 5'-triphosphate, or 2,3-diphosphoglycerate. Alternatively, the substrate may be a drug or a metabolite of a drug.

In some embodiments of the invention, the assays are used to quantify NADH, NADPH,  $\text{NAD}^+$ , or  $\text{NADP}^+$  itself. For example, such assays may be used to study  
15 biological systems in which these compounds are involved. Alternatively, NADH and NADPH have been used to treat a number of conditions including such as atherosclerosis, AIDS, cancer, chronic fatigue syndrome, Parkinson's and Alzheimer's and the assay of the invention can be used to measure NADH or NADPH in biological samples from subjects to whom these compounds have been administered.

The amount of substrate, enzyme, NADH, NADPH,  $\text{NAD}^+$ , or  $\text{NADP}^+$  employed  
20 in the assay typically depends on what is being measured and the system being used to measure the transfer of electrons through the reductase. One of the substrate, enzyme, NADH, NADPH,  $\text{NAD}^+$ , or  $\text{NADP}^+$  is typically present in an unknown amount as it is the substance being quantified. Typically, where that compound is not the one being  
25 quantified, the amount of:

- redox enzyme present is from 0 to 1000 $\mu\text{M}$ , 1 to 100 $\mu\text{M}$  , preferably from 5 to 75  $\mu\text{M}$ , and even more preferably from 5 to 50 $\mu\text{M}$ ;
- reductase present is from 0 to 1000 $\mu\text{M}$ , 0.001 to 100 $\mu\text{M}$  , preferably from 0.1 to 50  $\mu\text{M}$ , and even more preferably from 1 to 10 $\mu\text{M}$ ;
- 30 –  $\text{NAD}^+$ , or  $\text{NADP}^+$  present is from 0.1 to 100mM , preferably from 0.1 to 75mM, and even more preferably from 0.1 to 50mM; and/or
- redox active agent is from 1 to 100 mM, preferably from 1 to 25mM, and

even more preferably from 1 to 10mM.

Instead of using NADH, NADPH, NAD<sup>+</sup>, or NADP<sup>+</sup>, the assay may employ an analog of one of these compounds. Such analogs will typically be artificial or synthetic analogs chosen for particular characteristics such as their increased stability or the way in which they interact with a particular redox enzyme.

### *Reductases*

The use of a reductase in the assay of the invention allows the rapid transfer of electrons either from the NADH or NADPH to the redox active agent or *vice versa*.

The reductase typically receives two electrons from the NADH or NADPH and it is this acceptance of two electrons simultaneously followed by their rapid transfer individually to the redox active agent which allows a significant current to be generated, the size of which is directly proportional to the amount of substrate present and hence allowing meaningful, accurate results to be obtained.

The reductase employed may be any reductase capable of transferring the electrons rapidly enough to allow a detectable current to be generated. Preferred reductases include cytochrome P450 reductases. In particular, preferred reductases include the putidaredoxin reductase of the cytochrome P450<sub>cam</sub> enzyme system from *Pseudomonas putida*, the flavin (FAD/FMN) domain of the P450<sub>BM-3</sub> enzyme from *Bacillus megaterium*, spinach ferredoxin reductase, rubredoxin reductase, adrenodoxin reductase, nitrate reductase, cytochrome *b<sub>5</sub>* reductase, corn nitrate reductase, terpredoxin reductase and yeast, rat, rabbit and human NADPH cytochrome P450 reductases. Where a nitrate reductase is employed preferably corn nitrate reductase is used. Particularly preferred reductases for use in the invention are putidaredoxin reductase and flavin domain of P450<sub>BM-3</sub> as these are capable of particularly rapid electron transfer and hence allow optimal results to be obtained.

The reductase may be a recombinant protein or a naturally occurring protein which has been purified or isolated. The reductase may have been mutated to improve its performance such as to optimise the speed at which it carries out the electron transfer or its substrate specificity. The amount of reductase employed will depend on the exact nature of what is measured and the particular details of the assay but typically, the reductase will be present at a concentration of from 0 to 1000µM, 0.001 to 100 µM, preferably from 0.01 to 50 µM, more preferably from 0.1 to 25 µM, and even more preferably from 1 to 10 µM.

For putidaredoxin reductase, typically the amount of enzyme employed will be from 100 to 10,000 ca, preferably from 1000 to 5000 ca, more preferably from 2000 to 4000 ca and even more preferably will be 3000 ca. The ca is the unit of activity of putidaredoxin reductase in mediating the oxidation of NADH by ferricyanide and is  
5 defined as 1  $\mu$ mole of NADH oxidised per mg reductase per minute.

The general nature of reduction of small molecules by the reductase means the redox potential at which the small molecule mediator is detected can be tuned by standard methods of coordination chemistry so as to avoid interference from redox active molecules found in naturally occurring biological fluids.



#### 10 *Redox active agent*

A redox active agent is employed to accept the electrons from the reductase. Typically, the redox active agent will accept the electrons one at a time. The redox agent may be a redox active molecule or inorganic complex. The agent may be a naturally occurring electron acceptor such as a protein or may be a synthetic molecule. The agent  
15 will typically have at least two oxidation states to allow it to accept electrons from the reductase.

Preferably, the redox agent is an inorganic complex. The agent may comprise a metallic ion and will preferably will have at least two valencies. In particular, the agent may comprise a transition metal ion and preferred transition metal ions include those of  
20 cobalt, copper, iron, chromium, manganese, nickel, or ruthenium. The redox agent may be charged, for example it may be cationic or alternatively anionic. An example of a suitable cationic agent is a ruthenium complex such as  $\text{Ru}(\text{NH}_3)_6^{3+}$ , an example of a suitable anionic agent is a ferricyanide complex such as  $\text{Fe}(\text{CN})_6^{3-}$ . The reaction scheme for each respectively is:

25





The redox active agent may be hydrophobic, for example a ferrocenium complex may be used, or may be hydrophilic. Example of complexes which may be used include Cu(EDTA)<sup>2-</sup>, Fe(CN)<sub>6</sub><sup>3-</sup>, Fe(CN)<sub>5</sub>(O<sub>2</sub>CR)<sup>3-</sup>, Fe(CN)<sub>4</sub>(oxalate)<sup>3-</sup>, Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> and chelating amine ligand derivatives thereof (such as ethylenediamine), Ru(NH<sub>3</sub>)<sub>5</sub>(py)<sup>3+</sup>, ferrocenium and derivatives thereof with one or more of groups such as -NH<sub>2</sub>, -NHR, -NHC(O)R, and -CO<sub>2</sub>H substituted into one or both of the two cyclopentadienyl rings. Preferably the inorganic complex is Fe(CN)<sub>6</sub><sup>3-</sup>, Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup>, or ferrocenium monocarboxylic acid (FMCA).

The redox active agent interacts with the reductase and hence particular combinations of redox active agent and reductase may provide optimal results in terms of the rate of electron transfer or the charge produced or other desirable characteristics. For example, the reductase may have particular amino acids near its active site which mean that a hydrophobic redox agent is preferred or alternatively the region may contain positive or negatively charged residues or polar groups and hence an anionic or cationic redox agent may be more suitable. The particular pair of enzyme and redox agent is chosen to complement each other and hence to provide optimal results. Preferred pairings include Fe(CN)<sub>6</sub><sup>3-</sup> or Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> with putidaredoxin reductase or the flavin domain of P450<sub>BM-3</sub> and either Fe(CN)<sub>6</sub><sup>3-</sup> or Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> with spinach ferredoxin reductase. The choice of redox

agent may be selected based on the means used to detect the charge produced such as the electrode used.

The concentration of redox reagent used may vary depending on what is being measured and the other components in the assay, but typically is in the range of 0.01 to 500mM, preferably from 0.1 to 100 mM, more preferably from 1 to 50 mM, and even more preferably from 5 to 25mM.

The methods of the present invention do not encompass the use of diaphorase as the redox active agent or organic dyes such as Mendola blue and methyl-viologen.

#### *Detection methods*

The transfer of electrons to the redox agent to the redox agent is detected. This is preferably done by electrochemical means, although if desired NADH and NADPH concentrations can be measured at a wavelength of 340nm or the  $\text{Fe}(\text{CN})_6^{3-}$  concentration at 420nm.

Typically, the redox agent transfers electrons to an electrode generating a current. The current generated is typically proportional to the amount of substrate present in the sample and hence the amount of the substrate can be determined.

A typical sensor system based on electrochemical detection which may be used in the invention comprises a working electrode, for example constructed from carbon paste, platinum, gold or some such suitable conducting material, a reference electrode which is typically the AgCl/Ag electrode, and optionally a counter electrode. All electrodes are fabricated by techniques such as screen printing which are well known to those familiar with the art. A buffered solution of the dehydrogenase enzyme for converting the target analyte substrate to its product(s),  $\text{NAD}^+$  or  $\text{NADP}^+$ , a NADH or NADPH reductase, and the redox agent such as ferricyanide or  $\text{Ru}(\text{NH}_3)_6^{3+}$ , can be deposited onto the electrode system and dried.

The whole or part of the sensor system may be covered by a membrane or a number of membranes or filters for example, to separate red cells from a blood sample or to ensure that undesired substances or cells do not enter the sensor.

When a liquid sample such as blood is applied, the liquid typically enters the sensor compartment and redissolves the mixture of enzymes and redox agent. The target analyte is then oxidised, producing NADH or NADPH which rapidly reduces the reductase. The

reductase in turn rapidly reduces the redox agent such as  $\text{Ru}(\text{NH}_3)_6^{3+}$  to a reduced form, in this case  $\text{Ru}(\text{NH}_3)_6^{2+}$ , which is then oxidised by the working electrode set at the appropriate potential. The current produced will be proportional to the concentration of the target analyte.

5            In another embodiment of the invention the working electrode may be located away from the dehydrogenase/ $\text{NAD}^+$ /reductase/redox agent mixture to minimise fouling of the working electrode and thus improve sensor performance.

              By using a dehydrogenase with the appropriate substrate specificity and altering the reaction conditions, for example by including suitable chemical and biological components  
10            such as lipids, detergents, surfactants or other proteins, a rapid sensor may be constructed. Additionally another enzyme system can be used to convert a target analyte into a substance which is oxidised by the dehydrogenase and then detected by the present electrochemical method. For example a sensor to detect and or quantify triglycerides may be constructed where triglycerides are cleaved to glycerol and fatty acids by a suitable  
15            lipase and the glycerol may then be detected by glycerol dehydrogenase coupled to the reductase/redox agent system of the invention.

### *Samples*

              The assay of the invention can be used to monitor the presence of a particular analyte or enzyme in a wide array of samples. Typically, the samples analysed are liquid  
20            and will usually be an aqueous fluid. In particular, the sample may be a bodily fluid such as urine, serum, blood or amniotic fluid, cerebrospinal fluid (CSF) or alternatively may be a fluid such as milk, wine or juice or have been prepared from one of these. The sample may be culture medium from prokaryotic or eukaryotic cells and in particular from mammalian cells. The sample may be a foodstuff or drink or may be the product of an  
25            industrial process and the assay used to monitor the product of a compound or the incidence of byproducts or toxic compounds.

              Control samples may also be analysed. These may lack one or more of the substrate, redox enzyme, reductase, redox agent,  $\text{NADH}$ ,  $\text{NADPH}$ ,  $\text{NAD}^+$ , or  $\text{NADP}^+$ . The controls may be obtained from healthy individuals in order to compare them to those of a  
30            patient. Reference samples may be used which contain a known amount of the substrate or enzyme to be measured and hence allow calibration of the apparatus and/or standard curves

to be drawn up to be compared against the results for the unknown samples. The sample may be serially diluted and several dilutions analysed as the concentration of the substrate or enzyme to be measured might be too high to be effectively measured in undiluted form.

The method of the invention can be used to diagnose or assess the progression of various diseases or to determine the susceptibility of an individual to such diseases. Typically, the method is used to detect the presence or absence of, or to quantify the amount of a compound or enzyme associated with a disease state. For example, the method may be used to detect or quantify the amount of glucose in urine or blood from a diabetic or alternatively to measure the level of cholesterol or particular enzymes in a patient suffering from heart disease. The method may also be used to measure a compound or enzyme to determine when a drug or therapy needs to be administered to a patient or to measure how much of a drug remains or reached its target once administered. The method can also be used to detect and quantify drugs of abuse in samples from individuals.

The methods of the invention can be used to monitor lipid levels such as cholesterol or triglyceride levels and in particular may be used to quantify the levels of lipids in the blood or plasma. This may allow detection of individuals at risk of conditions associated with abnormal lipid levels such as those associated with elevated levels of a lipid or lipid deficiency. It may also allow monitoring of the progress of treatment of such a condition to assess whether lipid levels have returned to normal. Conditions include atherosclerosis, stroke, cardiovascular disease and heart attack as well as lipid deficiencies resulting from inadequate diet or metabolic defects.

The methods of the invention can also be used to monitor other metabolic defects such as those involved, for example, in amino acid metabolism. Such conditions include phenylketonuria (PKU) which may be monitored or detected by using phenyl alanine dehydrogenase as the redox enzyme in the system of the invention.

#### *Kits*

The invention also provides kits for carrying out the methods of the invention.

Typically, the kit will comprise:

- a reductase;
- a redox active agent; and
- a means for detecting the reduction of the redox active agent.

The kit may also comprise a redox enzyme, preferably a dehydrogenase, and/or the substrate for the redox enzyme. The redox enzyme, the substrate, reductase and redox active agent may be any of those discussed above.

5 The means for detecting the reduction of the redox agent may be an electrochemical means, such as an electrochemical cell or its constituent parts, or alternatively, but less preferably, may be spectrophotometric means.

The kit may include means for detecting and quantify current and optionally a computer system for analysing and displaying the results. The kit may also include various packing and suitable instructions detailing how to use the kit and how it should be stored.

## 10 EXAMPLES

The following Examples further illustrate the present invention.

### Example 1 - spectrophotometric analysis for putidaredoxin reductase

Putidaredoxin reductase is specific to NADH. The oxidation of NADH by  $\text{Fe}(\text{CN})_6^{3-}$  catalysed by putidaredoxin reductase was demonstrated by a spectrophotometric assay.

15 1.5 ml of an incubation mixture containing 50mM phosphate buffer, pH 7.4, 0.1nM putidaredoxin reductase, and 1 mM  $\text{K}_3\text{Fe}(\text{CN})_6$  was added to cuvettes. A spectrophotometer was used to measure the absorbance at 340nm and set to zero using a cuvette containing the incubation mixture alone.

20 NADH was then added to some of the cuvettes containing the incubation mixture as a 30mM stock in 50mM phosphate buffer, pH 7.4 to a final concentration of 300 $\mu\text{M}$  ( $A_{340\text{nm}}$  *ca.* 1.8) and absorbance at 340nm monitored. As shown by Figure 1a, the absorbance due to NADH decreased steadily with time as it was oxidised to  $\text{NAD}^+$  by ferricyanide acting as an oxidising agent in a reaction mediated by putidaredoxin reductase which catalysed the transfer of electrons from one to the other. If either the reductase or ferricyanide was omitted no change in absorbance was seen (Figure 1b). The reaction can also be monitored at the ferrocyanide absorption at 420 nm.

30 The  $\text{Ru}(\text{NH}_3)_6^{3+}$  reduction assay was carried out under identical conditions except that the putidaredoxin reductase concentration was 1 $\mu\text{M}$  and the  $\text{Ru}(\text{NH}_3)_6^{3+}$  concentration was 2mM. NADH was added to a final concentration of *ca.* 300  $\mu\text{M}$  ( $A_{340\text{nm}} = 1.8$ ) and the

NADH absorption at 340 nm was monitored. As shown in Figure 1c the NADH was oxidised in less than 2 minutes. When putidaredoxin reductase (PdR) was absent there was no detectable oxidation of NADH (Figure 1d).

Example 2 - spectrophotometric analysis for the P450<sub>BM-3</sub> flavin domain

5 The flavin domain of P450<sub>BM-3</sub> is specific for NADPH. The oxidation of NADPH by both Fe(CN)<sub>6</sub><sup>3-</sup> and Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> catalysed by the flavin domain of P450<sub>BM-3</sub> was demonstrated by spectrophotometric assays.

1.5 ml of an incubation mixture containing 50 mM phosphate buffer, pH 7.4, 50nM of the flavin domain of P450<sub>BM-3</sub>, and either 1 mM K<sub>3</sub>Fe(CN)<sub>6</sub> or 2 mM Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> was added to cuvettes. A spectrophotometer was used to measure the absorbance changes at the relevant wavelength.

For the ferricyanide reduction assay, the reaction was monitored at the 420nm absorptions of ferricyanide. NADPH was added to the sample cuvette as a 30 mM stock in 50 mM phosphate, pH 7.4 to a final concentration of ca. 500 μM (A<sub>340nm</sub> = 3.0) and the absorbance at 420 nm monitored. As shown in Figure 2, all the ferricyanide was reduced to the ferrocyanide in less than 80 seconds.

For the Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> reduction assay, the reaction was monitored at the NADPH absorptions at 340 nm. NADPH was added to a final concentration of ca.300 μM (A<sub>340nm</sub> = 1.8). As shown in Figure 3, all the NADPH was consumed in less than 90 seconds.

20 Example 3 - spectrophotometric analysis for spinach ferredoxin reductase

Spinach ferredoxin reductase is specific for NADPH. The oxidation of NADPH by both Fe(CN)<sub>6</sub><sup>3-</sup> and Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> catalysed by spinach ferredoxin reductase was demonstrated by spectrophotometric assays.

1.5ml of an incubation mixture containing 50mM phosphate buffer, pH 7.4, 0.05 units of spinach ferredoxin reductase, and either 1 mM K<sub>3</sub>Fe(CN)<sub>6</sub> or 2 mM Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup> was added to cuvettes. A spectrophotometer was used to measure the absorbance changes at the relevant wavelength.

For the ferricyanide reduction assay, the reaction was monitored at the 420nm absorptions of ferricyanide reduction assay, the reaction was monitored at the 420nm absorptions of ferricyanide. NADPH was added to the sample cuvette as a 30mM stock in

50mM phosphate, pH 7.4 to a final concentration of *ca.* 500  $\mu\text{M}$  ( $A_{340\text{nm}} = 3.0$ ) and the absorbance at 420nm monitored. As shown in Figure 4a, all the ferricyanide was reduced to the ferrocyanide in approximately 60 seconds. NADPH oxidation was much slower when either the reductase or ferricyanide was absent, see Figure 4b, 4c.

5 For the  $\text{Ru}(\text{NH}_3)_6^{3+}$  reduction assay, the reaction was monitored at the NADPH absorptions at 340nm. NADPH was added to a final concentration of *ca.* 400  $\mu\text{M}$  ( $A_{340\text{nm}} = 2.5$ ). As shown in Figure 5a, all the NADPH was consumed in less than 90 seconds. NADPH oxidation was much slower when either the reductase or  $\text{Ru}(\text{NH}_3)_6^{3+}$  was absent, see Figure 5b, 5c.

#### 10 Example 4 - electrochemical analysis

A sensor system based on electrochemical detection is constructed using a working electrode, constructed from carbon paste, platinum, gold or some such suitable conducting material, a reference electrode which is a AgCl/Ag electrode, and optionally a counter electrode. The electrodes may be prepared using screen printing.

15 A buffered solution of the dehydrogenase enzyme for converting the target analyte substrate to its product(s),  $\text{NAD}^+$  or  $\text{NADP}^+$ , a NADH or NADPH reductase, and ferricyanide or  $\text{Ru}(\text{NH}_3)_6^{3+}$  as a redox agent, can be deposited onto the electrode system and dried.

A liquid sample is applied to the system, the liquid enters the sensor compartment and redissolves the mixture of enzymes and redox agent. The target analyte is then oxidised, producing NADH or NADPH which rapidly reduces the reductase. The reductase may be putidaredoxin reductase where NADH is used or the flavin domain of P450<sub>BM-3</sub> or the spinach ferredoxin reductase where NADPH is employed. The reductase in turn rapidly reduces the redox agent such as  $\text{Ru}(\text{NH}_3)_6^{3+}$  or  $\text{Fe}(\text{CN})_6^{3-}$  to a reduced form, in other words to  $\text{Ru}(\text{NH}_3)_6^{2+}$  or  $\text{Fe}(\text{CN})_6^{4-}$  respectively. The  $\text{Ru}(\text{NH}_3)_6^{2+}$  or  $\text{Fe}(\text{CN})_6^{4-}$  is then oxidised by the working electrode set at the appropriate potential. The current produced is proportional to the concentration of the target analyte. Various solutions containing a known amount of the analyte may be employed to calibrate the system and/or to produce standard curves allowing the concentration of the analyte to be determined in the sample being tested.

20

25

30

CLAIMS

1. An electrochemical method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample comprising;

- contacting a reductase and a redox active agent with said sample; and
- 5 - measuring the quantity of reduced redox active agent produced by the reductase, by electrochemical means.

2. A method for monitoring the amount or activity of a redox enzyme or substrate, wherein the redox enzyme uses NADP, NADPH or NAD<sup>+</sup> or NADP<sup>+</sup> as a co-factor comprising carrying out the method of claim 1, wherein electron transfer between  
10 the redox active agent and an electrode is correlated to the amount or activity of the redox enzyme or substrate.

3. A method according to claim 1 or 2, wherein the NADH or NADPH are produced by the reduction of NAD<sup>+</sup> or NADP<sup>+</sup> by a redox enzyme which concomitantly oxidises a substrate.

15 4. A method according to claim 3, wherein the amount of NADH or NADPH formed is proportional to the amount of the redox enzyme present or the amount of its substrate and hence allows the detection, or quantification of the enzyme or substrate in the sample.

20 5. A method according to claim 2, 3 or 4, wherein the redox enzyme is a dehydrogenase.

6. A method according to any one of the preceding claims wherein the reductase is capable of accepting two electrons from NADH or NADPH.

25 7. A method according to any one of the preceding claims wherein the reductase is selected from putidaredoxin reductase of the cytochrome P450<sub>cam</sub> enzyme system from *Pseudomonas putida*, the flavin (FAD/FMN) domain of the P450<sub>BM-3</sub> enzyme from *Bacillus megaterium*, spinach ferredoxin reductase, rubredoxin reductase, adrenodoxin reductase, nitrate reductase, cytochrome *b<sub>5</sub>* reductase, corn nitrate reductase, terpredoxin reductase and yeast, rat, rabbit and human NADPH cytochrome P450 reductase or a functional derivative of any thereof.

30 8. A method according to any one of the preceding claims wherein the redox active agent is Fe (CN)<sub>6</sub><sup>3-</sup>, Ru(NH<sub>3</sub>)<sub>6</sub><sup>3+</sup>, or ferrocenium monocarboxylic acid (FMCA).



9. A method according to any one of the preceding claims wherein the reductase is specific for NADH.

10. A method according to claim 9 wherein the reductase is a putidaredoxin reductase.

5 11. A method according to any one of claims 1 to 8 wherein the reductase is specific for NADPH.

12. A method according to claim 11 wherein the reductase is the flavin domain of P450<sub>BM-3</sub> or is spinach ferredoxin reductase.

10 13. A method according to any one of the preceding claims which allows a monitoring of the amount of the substrate, enzyme, NADH or NADPH over time.

14. A method according to any preceding claim wherein the redox active agent is not diaphorase or an organic dye.

15. An electrochemical cell comprising:

- sample holding means;
- 15 – a source of reductase;
- a redox active agent; and
- means for detecting and/or quantifying any current generated.

16. An electrochemical cell according to claim 15, which can be used to carry out a method as defined in any one of claims 1 to 14.

Fig.1a.




Fig.1b.




Fig.1c.





Fig.1d.





**Fig.2.****Fig.3.**

Fig.4a.




Fig.4b.




Fig.4c.




Fig.5a.




Fig.5b.





Fig.5c.



**INTERNATIONAL SEARCH REPORT**

|   |
|---|
| International Application No<br>PCT/GB 03/00751 |
|---|

|   |  |   |
|---|--|---|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b>  |  |   |
| IPC 7   | G01N27/327   | C12Q1/00 C12Q1/26 C12Q1/32 H01M6/00   |
| According to International Patent Classification (IPC) or to both national classification and IPC   |  |   |
| <b>B. FIELDS SEARCHED</b>   |  |   |
| Minimum documentation searched (classification system followed by classification symbols)<br>IPC 7 C12Q G01N H01M   |  |   |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched   |  |   |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used)<br>EPO-Internal, WPI Data, PAJ   |  |   |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |  |   |
| Category °  | Citation of document, with indication, where appropriate, of the relevant passages                     | Relevant to claim No.   |
| X   | DE 196 19 056 A (SCHELLER FRIEDER PROF)<br>25 September 1997 (1997-09-25)<br>the whole document<br>--- | 1-16  |
| X   | US 5 783 056 A (HAMPP NORBERT ET AL)<br>21 July 1998 (1998-07-21)<br>the whole document<br>---         | 1-16  |
| X   | US 5 122 244 A (SCHAEFFLER JURGEN ET AL)<br>16 June 1992 (1992-06-16)<br>the whole document<br>---     | 1-16  |
| A   | EP 0 846 948 A (BAYER AG)<br>10 June 1998 (1998-06-10)<br>abstract; examples<br>-----<br>-/--          | 1,15  |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.   |  |   |
| ° Special categories of cited documents :   |  |   |
| *A* document defining the general state of the art which is not considered to be of particular relevance<br>*E* earlier document but published on or after the international filing date<br>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>*O* document referring to an oral disclosure, use, exhibition or other means<br>*P* document published prior to the international filing date but later than the priority date claimed |  | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<br>*&* document member of the same patent family |
| Date of the actual completion of the international search   | Date of mailing of the international search report   |   |
| 5 August 2003   | 13/08/2003   |   |
| Name and mailing address of the ISA<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax: (+31-70) 340-3016  | Authorized officer<br><br>Moreno, C  |   |



INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 03/00751

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |                       |
|--|--|-----------------------|
| Category °   | Citation of document, with indication, where appropriate, of the relevant passages                   | Relevant to claim No. |
| A  | US 5 393 615 A (COREY PAUL F ET AL)<br>28 February 1995 (1995-02-28)<br>abstract; examples<br>----   | 1,15                  |
| A  | US 5 264 092 A (SKOTHEIM TERJE ET AL)<br>23 November 1993 (1993-11-23)<br>abstract; examples<br>---- | 1,15                  |
| A  | US 5 306 413 A (HAYASHI RYUZO ET AL)<br>26 April 1994 (1994-04-26)<br>abstract; examples<br>-----    | 1,15                  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/00751

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date   |
|---|---------------------|----------------------------|---|
| DE 19619056                               | A                   | 25-09-1997                 | DE 19619056 A1 25-09-1997   |
| US 5783056                                | A                   | 21-07-1998                 | DE 4442253 A1 30-05-1996<br>CA 2163816 A1 29-05-1996<br>DE 59508908 D1 25-01-2001<br>EP 0714985 A1 05-06-1996<br>JP 8220055 A 30-08-1996  |
| US 5122244                                | A                   | 16-06-1992                 | DE 4003194 A1 08-08-1991<br>AT 146524 T 15-01-1997<br>AU 638899 B2 08-07-1993<br>AU 2108692 A 15-10-1992<br>AU 632659 B2 07-01-1993<br>AU 7018391 A 08-08-1991<br>BG 60694 B1 29-12-1995<br>CA 2035630 A1 04-08-1991<br>CN 1054666 A , B 18-09-1991<br>CS 9100261 A2 15-09-1991<br>DE 59108414 D1 30-01-1997<br>EP 0441222 A2 14-08-1991<br>ES 2097767 T3 16-04-1997<br>FI 910498 A 04-08-1991<br>HU 59756 A2 29-06-1992<br>IE 910343 A1 14-08-1991<br>IL 97121 A 31-10-1995<br>JP 2708281 B2 04-02-1998<br>JP 4213051 A 04-08-1992<br>KR 9408083 B1 01-09-1994<br>MX 24356 A 28-02-1994<br>NO 910394 A 05-08-1991<br>NZ 236931 A 27-06-1994<br>NZ 247446 A 27-06-1994<br>PL 288920 A1 07-09-1992<br>PL 168285 B1 31-01-1996<br>PT 96636 A 31-10-1991<br>US 5286362 A 15-02-1994<br>ZA 9100757 A 28-10-1992 |
| EP 0846948                                | A                   | 10-06-1998                 | US 5866353 A 02-02-1999<br>AU 726868 B2 23-11-2000<br>AU 4760297 A 11-06-1998<br>CA 2224034 A1 09-06-1998<br>EP 0846948 A1 10-06-1998<br>JP 10165199 A 23-06-1998   |
| US 5393615                                | A                   | 28-02-1995                 | AT 206466 T 15-10-2001<br>AU 674463 B2 19-12-1996<br>AU 8028094 A 10-08-1995<br>CA 2141494 A1 04-08-1995<br>DE 69522975 D1 08-11-2001<br>DE 69522975 T2 04-04-2002<br>EP 0667397 A1 16-08-1995<br>ES 2161787 T3 16-12-2001<br>JP 7310194 A 28-11-1995   |
| US 5264092                                | A                   | 23-11-1993                 | NONE  |
| US 5306413                                | A                   | 26-04-1994                 | DE 4310322 A1 07-10-1993  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/00751

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| US 5306413                             | A                | GB 2265718 A ,B         | 06-10-1993       |
|  |                  | JP 3319008 B2           | 26-08-2002       |
|  |                  | JP 6018478 A            | 25-01-1994       |
| -----                                  |                  |                         |                  |